Degarelix Acetate Patent Expiration
Degarelix Acetate is used for managing advanced prostate cancer and reducing side effects associated with GnRH agonist therapy. It was first introduced by Ferring Pharmaceuticals Inc
Degarelix Acetate Patents
Given below is the list of patents protecting Degarelix Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Firmagon | US10695398 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US10729739 | Methods of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
| Firmagon | US10973870 | Methods of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
| Firmagon | US11766468 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US11826397 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US5925730 | GnRH antagonists |
May 18, 2021
(Expired) | Ferring |
| Firmagon | US9415085 | Method of treating prostate cancer with GnRH antagonist | Apr 27, 2032 | Ferring |
| Firmagon | US9579359 | Method of treating prostate cancer with GnRH antagonist | Feb 10, 2029 | Ferring |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳